Post-translational modification of p53 in tumorigenesis

Nature Reviews Cancer

Volumn 4, Issue 10, 2004, Pages 793-805

  Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BLACK TEA EXTRACT; CAFFEINE; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIGALLOCATECHIN GALLATE; GLYCINE; GREEN TEA EXTRACT; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HYDROXYUREA; LYSINE; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; NEDD8 PROTEIN; PHYTOALEXIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MDM2; PROTEIN P53; RESVERATROL; SERINE; THEAFLAVIN; THREONINE; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UNINDEXED DRUG;

APOPTOSIS; BIOACCUMULATION; CANCER CELL; CANCER PREVENTION; CARCINOGENESIS; CELL AGING; CELL CYCLE; CELL KILLING; CELL TYPE; DIET THERAPY; DNA DAMAGE; DNA REPAIR; DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TRANSPORT; PROTEOMICS; REGULATORY MECHANISM; REVIEW; TEA;

ACETYLATION; ACETYLTRANSFERASES; ANTICARCINOGENIC AGENTS; CARCINOGENS; CELL TRANSFORMATION, NEOPLASTIC; DNA; GENES, P53; HUMANS; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; STRESS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN; ULTRAVIOLET RAYS;

EID: 4944255743     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1455     Document Type: Review

References (147)

1. Friedman, P. N., Chen, X., Bargonetti, J. & Prives, C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl Acad. Sci, USA 90, 3319-3323 (1993).
2. Davison, T. S., Yin, P., Nie, E., Kay, C. & Arrowsmith, C. H. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene 17, 651-656 (1998).
3. Mihara, M. et al. p53 has a direct apoptogenic role at the mitochondria. Mol, Cell 11, 577-590 (2003).
4. Olivier, M., Hussain, S. R, Caron de Fromentel, C., Hainaut, P. & Harris, C. C. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci. Publ. 157, 247-270 (2004).
5. Craven, R. J., Lightfoot, H. & Cance, W. G. A decade of tyrosine kinases: from gene discovery to therapeutics. Surg. Oncol. 12, 39-49 (2003).
6. Shaw, R, Freeman, J., Bovey, R. & Iggo, R. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12, 921-930 (1996).
7. Wesierska-Gadek, J., Bugajska-Schretter, A. & Cerni, C. ADP-ribosylation of p53 tumor suppressor protein: mutant but not wild-type p53 is modified. J, Cell Biochem, 62, 90-101 (1996).
8. Ito, A. et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J, 20, 1331-1340 (2001).
9. Espinosa, J. M. & Emerson, B, M. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8, 57-69 (2001). Questions the importance of acetylation of p53.
10. Nakamura, S., Roth, J. A. & Mukhopadhyay, T Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2-dependent protein degradation and ubiquitination. Mol. Cell Biol. 20, 9391-9398 (2000).
11. Barlev, N. A. et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell. 8, 1243-1254 (2001).
12. Luo, J., Su, F., Chen, D., Shiloh, A. & Gu, W. Deacetylation of p53 modulates is effect on cell growth and apoptosis. Nature 408, 377-381 (2000).
13. Juan,L. J. et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275, 20436-20443 (2000).
14. SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 107, 149-169 (2001).
15. Luo, J. et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107, 137-148 (2001).
16. Rodriguez, M. S., Desterro, J. M., Lain, S., Lane, D. P. & Hay, R. T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome- mediated degradation. Mol. Cell Biol. 20, 8458-8467 (2000).
17. Xirodimas, D. P., Saville, M. K., Bourdon, J. C., Hay, R. T. & Lane, D. P. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118, 83-97 (2004). The first paper to report neddylation as a post-translational modification of p53.
18. Hupp, T. R. & Lane, D. P. Allosteric actuation of latent p53 tetramers, Curr. Biol. 4, 865-875 (1994).
19. Gatti, A., Li, H. H., Traugh, J. A. & Liu, X. Phosphorylation of human p53 on Thr-55. Biochemistry 39, 9837-9842 (2000).
20. Waterman, M. J., Stavridi, E. S., Waterman, J. L. & Halazonetis, T. D. ATM-dependent actuation of p53 involes dephosphorylation and association with 14-3-3 proteins. Nature Genet 19, 175-178(1998).
21. Sakaguchi, K. et al. Damage-mediated phosphorylation of human p53 three-nine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J, Biol. Chem, 275, 9278-9283 (2000).
22. Dumaz, N., Milne, D. M. & Meek, D. W. Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphoryiation of serine 15. FEBS Lett. 463, 312-316 (1999).
23. 2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell. Biol. 21, 2743-2754 (2001).
24. Haneda, M. et al. Protein phosphatasel, but not protein phosphatase 2A, dephosphorylates DMA-damaging stress-induced phospho-serine 15 of p53. FEBS Lett. 567, 171-174 (2004).
25. Fan, G., Ma, X., Wong, P. Y., Rodrigues, C. M. & Steer, C. J. p53 dephosphorylation and p21 (Cip1/Waf1) translocation correlate with caspase-3 actuation in TGF-β1-induced apoptosis of HuH-7 cells. Apoptosis 9, 211-221 (2004).
26. ARF, and p300/CBP during the cell cycle and after exposure to ultraviolet irradiation. Cancer Res. 60, 896-900 (2000).
27. Ulrich, S. J. et al. Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. Proc. Natl Acad. Sci. USA 90, 5954-5958 (1993). One of the first reports to show that post-translational modification of mutant p53 differs from wild-type p53.
28. Higashimoto, Y. et al. Human p53 is phosphorylated on serines 6 and 9 in response to DMA damage-inducing agents. J. Biol. Chem. 275, 23199-23203 (2000).
29. Kao, C. F., Chen, S. Y., Chen, J. Y. & Wu Lee, Y. H. Modulation of p53 transcription regulatory activity and post-translational modification by hepatitis C virus core protein. Oncogene 23, 2472-2483 (2004).
30. Ray, R. B. & Ray, R. Hepatitis C virus core protein: intriguing properties and functional relevance. FEMS Microbiol. Lett. 202, 149-156 (2001).
31. Frazier, M. W. et al. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol. Cell. Biol. 18, 3735-3743 (1998).
32. Atema, A. & Chene, P. The gain of function of the p53 mutant Asp281 Gly is dependent on its ability to form tetramers. Cancer Lett. 185, 103-109 (2002).
33. Chene, P. In vitro analysis of the dominant negative effect of p53 mutants. J. Mol. Biol. 281, 205-209 (1998).
34. Chan, W. M., Siu, W. Y., Lau, A. & Poon, R. Y. How many mutant p53 molecules are needed to inactivate a tetramer? Mol. Cell. Biol. 24, 3536-3551 (2004).
35. Nicholls, C. D., McLure, K. G., Shields, M. A. & Lee, P. W. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J. Biol. Chem. 277, 12937-12945 (2002).
36. Willis, A., Jung, E. J., Wakefield, T. & Chen, X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23, 2330-2338 (2004).
37. Minamoto, T. et al. Distinct pattern of p53 phosphorylation in human tumors. Oncogene 20, 3341-3347 (2001). One of only a few studies that examined the phosphorylation pattern in a range of cancer cell types that express mutant p53.
38. Melnikova, V. O., Santamaria, A. B., Bolshakov, S. V. & Ananthaswamy, H. N. Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase. Oncogene 22, 5958-5966 (2003).
39. Sakaguchi, K. et al. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36, 10117-10124 (1997).
40. Furihata, M. et al. Frequent phosphorylation at serine 392 in overexptessed p53 protein due to missense mutation in carcinoma of the urinary tract. J. Pathol. 197, 82-88 (2002).
41. Yap, D. B. et al. Ser392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res. 64, 4749-4754 (2004).
42. Zhong, S., Salomoni, P. & Pandolfi, P. P. The transcriptional role of PML and the nuclear body. Nature Cell Biol. 2, E85-E90 (2000).
43. Guo, A. et al. The function of PML in p53-dependent apoptosis. Nature Cell Biol. 2, 730-736 (2000).
44. Borden, K. L. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol. Cell. Biol. 22, 5259-5269 (2002).
45. Negorev, D. & Maul, G. G. Cellular proteins located at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 20, 7234-7242 (2001).
46. Muratani, M. et al. Metabolic-energy-dependent movement of PML bodies within the mammalian cell nucleus. Nature Cell Biol. 4, 106-110 (2002).
47. Pearson, M. et al, PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406, 207-210 (2000). One of the first studies to report that PML NBs are required for RAS-induced p53 acetylation (at Lys382) by the CBP acetyltransferase.
48. Langley, E. et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 21, 2383-2396 (2002).
49. Louria-Hayon, I. et al. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J. Biol. Chem, 278, 33134-33141 (2003).
50. Insinga, A. et al. Impairment of p53 acerylation, stability and function by an oncogenic transcription factor. EMBO J. 23, 1144-1154 (2004).
51. Ishov, A. M. et al. PML is critical for ND10 formation and recruits the PML-interacting protein daxx to this nuclear structure when modified by SUMO-1. J. Cell Biol. 147, 221-234 (1999).
52. Rodriguez, M. S. et al. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18, 6455-6461 (1999).
53. Gostissa, M. et al. Actuation of p53 by conjugation to the ubiquitin-like protein SUMO-1. EMBO J. 18, 6462-6471 (1999).
54. Melchior, F. & Hengst, L. SUMO-1 and p53. Cell Cycle 1, 245-249 (2002).
55. Chen, L. & Chen, J. MDM2-ARF complex regulates p53 sumoylation. Oncogene 22, 5348-5357 (2003).
56. ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2. FEBS Lett 528, 207-211 (2002).
57. Girdwood, D. et al. P300 transcriptional repression is mediated by SUMO modification, Mol. Cell 11, 1043-1054 (2003).
58. Kimn, Y. H., Choi, C. Y. & Kim, Y. Covalent modification of the homeodomain-interacting protein kinase 2 (H1PK2) by the ubiquitin-like protein SUMO-1. Proc. Natl Acad. Sci. USA 96, 12350-12355 (1999).
59. Fuchs, S. Y., Adler, V., Buschmann, T., Wu, X. & Ronal, Z. Mdm2 association with p53 targets its ubiquitination. Oncogene 17, 2543-2547 (1998).
60. Honda, R., Tanaka, H. & Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27 (1997).
61. Biattner, C., Hay, T., Meek, D. W. & Lane, D. P. Hypophosphorylation of Mdm2 augments p53 stability. Mol. Cell. Biol 22, 6170-6182 (2002).
62. Li, M. et al. Mono-versus polyubiquitination; differential control of p53 fate by Mdm2. Science 302, 1972-1975 (2003). Indicates that the level of MDM2 activity determines whether p53 will be exported or degraded in the nucleus.
63. Knights, C. D., Liu, Y, Appella, E. & Kulesz-Martin, M. Defective/p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification. J. Biol. Chem. 278, 52890-52900 (2003).
64. Lavin, M. F. & Shiloh, Y. The genetic defect in ataxia- telangiectasia. Annu. Rev, Immunol. 15, 177-202 (1997).
65. Appella, E. & Anderson, C. W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268, 2764-2772 (2001).
66. ARF. Cancer Res. 64, 221-228 (2004).
67. ARF in homeostatic tissues. Mol. Cell. Biol. 24, 186-191 (2004). Indicates that different p53 regulatory pathways are activated in normal and stressed cells.
68. Finch, R. A. et al. mdmx is a negative regulator of p53 activity vivo. Cancer Res. 62, 3221-3225 (2002).
69. Migliorini, D, et al. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Mol. Cell. Biol. 22, 5527-5538 (2002).
70. Ramos, Y. F. et al. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Cancer Res. 61, 1839-1842 (2001).
71. Li, M. et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416, 648-653 (2002). The first paper to identify HAUSP as a protein that functions to de-ubiquitylate p53.
72. Um, S. K., Shin, J. M. Kim, Y. S. & Baek, K. H. Identification and characterization of murine mHAUSP encoding a deubiquitinating enzyme that regulates the status of p53 ubiqurtination. Int. J. Oncol. 24, 357-364 (2004).
73. Li, M., Brooks, C. L., Kon, N. & Gu, W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol. Cell 13, 879-886 (2004).
74. Pitot, H. C. & Dragan, Y. P. The multistage nature of chemically induced hepatocarcinogenesis in the rat Drug Metab. Rev. 26, 209-220 (1994).
75. Lee, Y. I., Lee, S., Das, G. C., Park, U. S. & Park, S. M. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene 19, 3717-3726 (2000).
76. Chaturvedi, V., Qin, J. Z., Stennett, L., Choubey, D. & Nickoloff, B. J. Resistance to UV-induced apoptosis in human keratinocytes during accelerated senescence is associated with functional inactivation of p53. J. Cell Physiol. 198, 100-109 (2004).
77. Banin, S. et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674-1677 (1998).
78. Canman, C. E. et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677-1679 (1998).
79. Khanna, K. K. et al. ATM associates with and phosphorylates p53: mapping the region of interaction. Nature Genet 20, 398-400 (1998).
80. Zhang, Y., Ma, W. Y., Kaji, A., Bode, A. M. & Dong, Z. Requirement of ATM in UVA-induced signaling and apoptosis. J. Biol. Chem. 277, 3124-3131 (2002). The first study to show that ATM is activated differentially in response to various wavelengths of ultraviolet irradiation.
81. Unsal-Kacmaz, K., Makhov, A. M., Griffith, J. D. & Sancar, A. Preferential binding of ATR protein to UV-damaged DNA. Proc. Natl Acad. Sci. USA 99, 6673-6678 (2002).
82. Hong, W. K. General keynote: the impact of cancer chemoprevention. Gynecol. Oncol. 88, S56-S58 (2003).
83. Forbes, I. J., Zalewski, P. D., Giannakis, C. & Cowled, P. A. Induction of apoptosis in chronic lymphocyte leukemia cells and its pravention by pharbol ester. Exp. Cell Res. 198, 367-372 (1992).
84. Song, Q., Baxter, G. D., Kovacs, E. M., Findlk, D. & Lavin, M. F. Inhibition of apoptosis in human tumour cells by okadaic acid. J. Cell Physiol. 153, 550-556 (1992).
85. Tomei, L. D., Kanter, P. & Wenner, C. E. Inhibition of radiation-induced apoptosis in vitro by tumor promoters. Biochem. Biophys. Res. Commun. 155, 324-331 (1988).
86. Dercks, W. & Creasy, L. L. The significance of stilbene phytoalexins in the Plasmopara viticola-grapevine interaction. Physiol. Mol. Plant Path. 34, 189-202 (1989).
87. Kim, Y. A. et al. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells, Oncol Rep. 11, 441-146 (2004).
88. Shih, A., Davis, F. B., Lin, H. Y. & Davis, P. J. Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK-and p53-dependent mechanism. J. Clin. Endocrinol. Metab, 87, 1223-1232 (2002).
89. She, Q. B. et al. Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved. Oncogene 22, 2143-2150 (2003).
90. She, Q. B., Bode, A. M., Ma, W. Y., Chen, N. Y. & Dong, Z. Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein Kinases and p38 kinase. Cancer Res. 61, 1604-1610 (2001).
91. Huang, C., Ma, W. Y., Goranson, A. & Dong, Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20, 237-242 (1999).
92. Lu, J., Ho, C. T., Ghai, G. & Chen, K. Y. Differential effects of theafiavin monogallates on cell growth, apoptosis, and Cox-2 gene expression in cancerous versus normal cells. Cancer Res. 60, 6465-6471. (2000).
93. Hastak, K. et al. Role of p53 and NF-κB in epigallocatechin-3- gallate-induced apoptosis of LNCaP cells. Oncogene 22, 4851-1859 (2003).
94. Kuo, P. L. & Lin, C. C. Green tea constituent (-)-epigallocatechin-3- gallate inhibits Hep G2 cell proliferation and induces apoptosis through p53-dependent and Fas-mediated pathways. J. Biomed. Sci. 10, 219-227 (2003).
95. Sah, J. F., Balasubramanian, S., Eckert, R. L. & Rorke, E. A. Epigatlocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J. Biol. Chem. 279, 12755-12762 (2004).
96. He, Z. et al. Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res. 63, 4396-4401 (2003).
97. 1 phase arrest in JB6 cells. Cancer Res. 64, 3344-3349 (2004).
98. Sarkaria. J. N. et al, Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59, 4375-4382 (1999).
99. Cortez, D. Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM-and Rad3-related (ATR) protein kinases. J. Biol. Chem. 278, 37139-37145 (2003).
100. Chen, J., Lin, J. & Levine, A. J. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med 1, 142-152 (1995).
101. Stommel, J. M. et al. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular boalization and p53 activity by NES masking. EMBO J. 18, 1660-1672 (1999).
102. Liu, L. et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19, 1202-1209 (1999).
103. Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J. & Livingston, D. M. Binding and modulation of p53 by p300/CBP coaetivators. Nature 387, 823-827 (1997).
104. Gu, W. & Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
105. Avantaggiati, M. L. et al. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89, 1175-1184 (1997).
106. Luo, J. et al. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc, Natl Acad. Sci. USA 101, 2259-2264 (2004).
107. Wang, Y, H., Tsay, Y. G., Tan, B. C., Lo, W. Y. & Lee, S. C. Identification and characterization of a novel p300-mediated p53 acetylation site, lysine 305, J. Biol. Chem. 278, 25568-25576 (2003).
108. Wang, X., Taplick, J., Geva, N. & Oren, M. Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett. 561, 195-201 (2004).
109. Jin, Y., Zeng, S. X., Lee, H. & Lu, H. MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. J, Biol. Chem. 279, 20035-20043 (2004).
110. +- dependent protein deacetylase activity in the Sir2 protein family. Proc. Natl Acad. Sci. USA 97, 6658-6663 (2000).
111. Florenes, V. A., Skrede, M., Jorgensen, K. & Nesland, J. M. Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival. Melanoma Res. 14, 173-181 (2004).
112. Tyner, S. D. et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45-53 (2002).
113. Ferbeyre, G. et al, PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 14, 2015-2027 (2000).
114. Bischof, O. et al. Deconstructing PML-induced premature senescence. EMBO J. 21, 3358-3369 (2002).
115. de Stanchira, E. et al. PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 13, 523-535 (2004).
116. Fuchs, S. Y. et al. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12, 2658-2663 (1998). One of the first reports illustrating a function for JNX in the regulation of p53.
117. Fuchs, S. Y., Adler. V., Pincus, M. R. & Ronai, Z. MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl Acad. Sci. USA 95, 10541-10546 (1998).
118. Scheffner, M., Huibregtse, J. M., Vierstra, R. D. & Howley, P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505 (1993).
119. Leng, R. P. et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 112, 779-791 (2003).
120. Dornan, D. et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 429, 86-92 (2004).
121. Bech-Otschir, D. et al. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J. 20, 1630-1639 (2001).
122. Li, H. H., Li, A. G., Sheppard, H. M. & Liu, X. Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol. Cell 13, 867-878 (2004).
123. Katayama, H. et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nature Genet. 36, 55-62 (2004).
124. Pohier, E. et al. The Barren's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol. Cell Proteomics 3, 534-547 (2004).
125. Ohtsuka, T., Jensen, M. R., Kim, H. G., Kim, K. T. & Lee, S. W. The negative role of cyolin G in ATM-dependent p53 activation. Oncogene 23, 5405-5408 (2004).
126. +/+ cells. J. Biol. Chem. 274, 11022-11029 (1999).
127. Derenzini, M. The AgNORs. Micron 31, 117-120 (2000).
128. Chan, W. Y. et al. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry 28, 1033-1039 (1989).
129. Maiguel, D. A., Jones, L., Chakravarty, D., Yang, C. & Carrier, F. Nucleophosmin sets a threshold for p53 response to UV radiation. Mol. Cell. Biol. 24, 3703-3711 (2004).
130. Saito, S, et al. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J. Biol. Chem. 277, 12491-12494 (2002).
131. Tibbetts, R. S. et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13, 152-157 (1999).
132. Blaydes, J. P. et al. Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription. J. Biol. Chem. 276, 4699-4708 (2001).
133. Chehab, N. H., Malikzay, A., Stavridi, E. S. & Halazonetis, T. D. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage, Proc. Natl Acad. Sci. USA 96, 13777-13782 (1999).
134. Unger, T. et al. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18, 1805-1814 (1999).
135. Knippschild, U. et al. p53 is phosphorylated in vitro and in vivo by the δ and ε isoforms of casein kinase 1 and enhances the level of casein kinase 1δ in response to topoisomerase-directed drugs. Oncogens 15, 1727-1736 (1997).
136. Shieh, S. Y., Ikeda, M., Taya, Y. & Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibftion by MDM2. Cell 91, 325-334 (1997).
137. She, Q. B., Chen, N. & Dong, Z. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J. Biol. Chem. 275, 20444-20449 (2000).
138. Yeh, P. Y., Chuang, S. E., Yen, K. H., Song, Y. C. & Cheng, A. L. Nuclear extracellular signal-regulated kinase 2 phosphorylates p53 at Thr55 in response to doxorubidn. Biochem. Biophys. Res. Commun. 284, 880-886 (2001).
139. Keller, D. M. et al. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell 7, 283-292 (2001).
140. Qu, L. et al. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3β. Genes Dev. 18, 261-277 (2004).
141. Hofmann, T. G. et al. Regulation of p53 activity by is interaction with homeodomain-interacting protein kinase-2. Nature Cell Biol. 4, 1-10 (2002).
142. D'Orazi, G. et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nature Cell Biol. 4, 11-19 (2002).
143. She, Q. B., Ma, W. Y. & Dong, Z. Role of MAP kinases in UVB-induced phosphorylation of p53 at serine 20. Oncogene 21, 1580-1589 (2002).
144. Bulavin, D. V. et al. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J. 18, 6845-6854 (1999).
145. Huang, C., Ma, W. Y., Maxiner, A., Sun, Y. & Dong, Z. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J. Biol. Chem. 274, 12229-12235 (1999).
146. Chemov, M. V., Bean, L. J., Lernen N. & Stark, G. R. Regulation of ubiquitination and degradation of p53 in unstressed cells through C-terminal phosphorylation. J. Biol. Chem. 276, 31819-31824 (2001).
147. Cuddihy, A. R., Wong, A. H., Tam, N. W., Li, S. & Koromilas, A. E. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogens 18, 2690-2702 (1999).